IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have received an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $231.80.

Several research firms have recently commented on IQV. Jefferies Financial Group reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Finally, Truist Financial decreased their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently made changes to their positions in IQV. Eubel Brady & Suttman Asset Management Inc. acquired a new stake in IQVIA in the third quarter worth approximately $14,278,000. OPTIMAS CAPITAL Ltd bought a new stake in shares of IQVIA in the 3rd quarter worth $4,008,000. Eagle Rock Investment Company LLC lifted its holdings in shares of IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after buying an additional 11,657 shares during the period. Amundi boosted its stake in IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after buying an additional 405,250 shares in the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd acquired a new position in IQVIA during the third quarter worth about $7,368,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQVIA stock opened at $179.09 on Monday. IQVIA has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The company has a market capitalization of $30.39 billion, a price-to-earnings ratio of 22.79, a price-to-earnings-growth ratio of 1.72 and a beta of 1.40. The firm’s fifty day moving average price is $212.19 and its 200 day moving average price is $208.13.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same period last year, the firm earned $3.12 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts forecast that IQVIA will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.